Compare Revvity Inc (RVTY) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs SOLAI Limited — how do they compare? Revvity Inc trades at $154.34 (market cap $16.98B), while SOLAI Limited trades at $3.72 (market cap $880.09M). The key difference: Revvity Inc is far larger — about 19.3× SOLAI Limited's market cap, and Revvity Inc pays a 0.18% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and SOLAI Limited for 40 Days on average.
| RVTY | SLAI | |
|---|---|---|
Market Cap | $16.98B | $880.09M |
Volume | 1,456,900 | 122,720 |
Sector | Health | Technology |
52-Week High | $157.36 | $21.63 |
52-Week Low | $82.26 | $2.74 |
Typical Hold Time | 12 Days | 40 Days |
Enterprise Value | $19.30B | $879.73M |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
SLAI trades at $3.72 with no recent price movement. The technical picture is bullish based on moving averages and oscillators, though the stock faces delisting proceedings from the NYSE. Fundamentally, the company shows severe distress with negative gross and net income margins, high revenue decline, and substantial losses despite a low P/B ratio. Recent news highlights governance changes amid exchange compliance issues.
The outlook is highly risky due to financial instability and delisting threat. Investment opportunity exists only for speculative traders betting on a turnaround, given the low valuation multiple. Key risks include continued cash burn, inability to achieve profitability, and loss of major exchange listing impacting liquidity and investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
